Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer

Abstract

PURPOSE: Treatment goals for patients with metastatic cancer include prolongation and maintenance of quality of life. Patients and oncologists have questioned the current paradigm of initial dose selection for systemic therapy; however, data on oncologists' dose selection strategies and beliefs are lacking. METHODS: We conducted an electronic international survey of medical oncologists who treat patients with breast and/or gastrointestinal cancers. Survey questions addressed experiences with, and attitudes toward, dose reduction at initiation (DRI) of a new systemic therapy for patients with metastatic cancer. RESULTS: Among 3,099 eligible oncologists, 367 responded (response rate 12%). Most (52%) reported using DRI at least 10% of the time to minimize toxicities. Gastrointestinal specialists were more likely to report DRI ≥ 10% of the time (72% v 50% of generalists and 51% of breast specialists, P < .005). Of those who dose reduced ≥ 10% of the time, 89% reported discussing potential tradeoffs between efficacy and toxicity with patients. Overall, 65% agreed it is acceptable to lower starting doses to reduce side effects even if it compromises efficacy; younger clinicians were more likely to agree ( P < .005). There was strong support (89%) for future trials to determine optimal effective, rather than maximum tolerated, dose. CONCLUSION: Oncology practice varies with regard to discussion and individualized selection of starting doses in the metastatic setting. This study demonstrates a need for consideration of shared decision making regarding initial dose selection and strong support among oncologists for clinical studies to define optimal dosing and best practices for individualizing care.

Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus

“…An American Society of Clinical Oncology (ASCO) survey published in 2022 found that 41% of oncologists who treat breast and/or gastrointestinal cancer patients with capecitabine regularly prescribed it at a starting dose level lower than 1250 mg/m 2 . 26 Based on available data, in December 2022, there was a major update to the label of capecitabine which included new indications and also the addition of 1000 mg/m 2 (twice daily) as starting dose for patients with metastatic breast cancer. 27 While there was an abundance of data to support lower dosing for capecitabine, other oncology drugs that have been approved more recently and have been prescribed to a narrower patient population may not have the necessary data available.…”

Optimizing the doses of cancer drugs after usual dose finding

“…Younger generations of oncologists are increasingly willing to empirically use lower doses of drug in an effort to preserve quality of life, even when that might entail a tradeoff in efficacy. 80 Oncologists are increasingly willing to enroll patients in trials that seek lower toxicity, cost, and patient burden. 81 Oncologists are willing to discuss flexible approaches to dosing that may better balance toxicity and efficacy, particularly in metastatic disease.…”

Dynamic, personalized dose selection platform, CURATE.AI, in patients with solid tumors: case series and pilot feasibility trial

“…To avoid toxicity, more than half of the oncologists prescribe initiation doses that are lower than MTD at least 10% of the time. 3 Alternative strategies include adaptive dose modulations based on evolutionary-based modelling. 4,5 CURATE.AI is an indication-agnostic, AI-derived platform that utilizes a patient's own, prospectivelycalibrated small dataset to create an N-of-1 pro le -analogous to a digital twin -that dynamically personalizes only that patient's dose recommendations.…”